

Nail Fatkhutdinov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2986537/publications.pdf>

Version: 2024-02-01

16
papers

1,185
citations

567247

15
h-index

940516

16
g-index

16
all docs

16
docs citations

16
times ranked

2153
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | NAD+ metabolism governs the proinflammatory senescence-associated secretome. <i>Nature Cell Biology</i> , 2019, 21, 397-407. | 10.3 | 232 |
| 2 | HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. <i>Journal of Cell Biology</i> , 2016, 215, 325-334. | 5.2 | 132 |
| 3 | BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. <i>Cell Reports</i> , 2017, 21, 3398-3405. | 6.4 | 130 |
| 4 | N6-Methylation of Adenosine of <i>FZD10</i> mRNA Contributes to PARP Inhibitor Resistance. <i>Cancer Research</i> , 2019, 79, 2812-2820. | 0.9 | 127 |
| 5 | HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 5482-5489. | 0.9 | 86 |
| 6 | NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. <i>Cancer Research</i> , 2020, 80, 890-900. | 0.9 | 83 |
| 7 | EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. <i>Cancer Cell</i> , 2020, 37, 157-167.e6. | 16.8 | 79 |
| 8 | Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , 2018, 22, 3393-3400. | 6.4 | 77 |
| 9 | ARID1A promotes genomic stability through protecting telomere cohesion. <i>Nature Communications</i> , 2019, 10, 4067. | 12.8 | 40 |
| 10 | SWI/SNF catalytic subunitsâ€™ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. <i>Nature Communications</i> , 2018, 9, 4116. | 12.8 | 38 |
| 11 | Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence. <i>Nature Communications</i> , 2020, 11, 908. | 12.8 | 36 |
| 12 | Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. <i>Nature Cancer</i> , 2021, 2, 189-200. | 13.2 | 36 |
| 13 | ARID1A spatially partitions interphase chromosomes. <i>Science Advances</i> , 2019, 5, eaaw5294. | 10.3 | 35 |
| 14 | Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. <i>Molecular Cancer Research</i> , 2016, 14, 767-775. | 3.4 | 27 |
| 15 | ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1564-1572.e4. | 0.7 | 20 |
| 16 | Harnessing mutual exclusivity between TP53 and ARID1 A mutations. <i>Cell Cycle</i> , 2017, 16, 2313-2314. | 2.6 | 7 |